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Abstract: cAMP is the archetypal and ubiquitous second messenger utilised for the fine control of
many cardiovascular cell signalling systems. The ability of cAMP to elicit cell surface receptor-
specific responses relies on its compartmentalisation by cAMP hydrolysing enzymes known
as phosphodiesterases. One family of these enzymes, PDE4, is particularly important in the
cardiovascular system, where it has been extensively studied and shown to orchestrate complex,
localised signalling that underpins many crucial functions of the heart. In the cardiac myocyte,
cAMP activates PKA, which phosphorylates a small subset of mostly sarcoplasmic substrate proteins
that drive β-adrenergic enhancement of cardiac function. The phosphorylation of these substrates,
many of which are involved in cardiac excitation-contraction coupling, has been shown to be
tightly regulated by highly localised pools of individual PDE4 isoforms. The spatial and temporal
regulation of cardiac signalling is made possible by the formation of macromolecular “signalosomes”,
which often include a cAMP effector, such as PKA, its substrate, PDE4 and an anchoring protein such
as an AKAP. Studies described in the present review highlight the importance of this relationship
for individual cardiac PKA substrates and we provide an overview of how this signalling paradigm
is coordinated to promote efficient adrenergic enhancement of cardiac function. The role of PDE4
also extends to the vascular endothelium, where it regulates vascular permeability and barrier
function. In this distinct location, PDE4 interacts with adherens junctions to regulate their stability.
These highly specific, non-redundant roles for PDE4 isoforms have far reaching therapeutic potential.
PDE inhibitors in the clinic have been plagued with problems due to the active site-directed nature of
the compounds which concomitantly attenuate PDE activity in all highly localised “signalosomes”.
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1. Introduction
Cyclic 3′,5′-adenosine monophosphate (cAMP) was the first second messenger molecule to be
discovered, and has been researched tirelessly in the context of numerous physiological systems.
Much of the current understanding of cAMP signalling, however, has come from studying its function
in the cardiovascular system, where it has major roles in the heart and vessels [1]. In the heart, cAMP
influences a multitude of processes from contractility and hypertrophy of myocytes to apoptosis and
cell survival [2]. In the vasculature, effects on smooth muscle cell contraction and relaxation, as well as
endothelial cell permeability has been attributed to cAMP signalling processes [3]. Additionally, cAMP
can modify cell proliferation, migration, differentiation, and response to stress [4–7]. cAMP produces
these vast cellular effects by activating four types of effector proteins: protein kinase A (PKA),
exchange protein directly activated by cAMP (EPAC), cyclic nucleotide activated ion channels (CNGC),
and popeye domain containing proteins (POPDC). The present review will focus on the effects of
PKA and EPAC. PKA functions to phosphorylate substrate proteins, while EPAC activates the RAS
superfamily of enzymes [8]. The present review will focus on the ways in which phosphodiesterase
4 (PDE4) enzymes modify cAMP’s ability to produce these varied physiological effects within the
cardiovascular system.
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2. cAMP Signalling and Compartmentalisation
The small, highly diffusible molecule, cAMP can be produced by both membrane-bound adenylyl
cyclase (mAC) and soluble adenylyl cyclase (sAC) in response to various stimuli, such as the activation
of various Gs-coupled receptors, which activates mAC [9]. Its properties suggest that it would quickly
diffuse throughout the cell, simultaneously activating all effector proteins almost instantly. In striking
contrast, it was shown by Larry Brunton and colleagues in the early 1980s that cAMP can cause
multiple discrete receptor specific responses in the same cells [10,11]. To explain this phenomenon,
it was quickly postulated, and eventually proven, that compartmentalisation of cAMP signalling
underpins receptor specific responses by restricting the number and identity of PKA substrates that
get phosphorylated in response to each specific receptor ligation [12,13]. Such fine control of one
ubiquitous second messenger that acts to activate only discrete pools of PKA is made possible by the
subcellular localisation of proteins that degrade cAMP. This function is attributed to a super-family
of enzymes called phosphodiesterases (PDEs). PDEs are the only known route to the hydrolysis of
cAMP and this function empowers these enzymes to act as “sinks”, reducing cAMP concentration in
localised areas preventing the inappropriate phosphorylation of PKA substrates under basal conditions.
Following receptor activation, however, this situation can be altered to allow cAMP concentrations
to exceed the activation threshold of PKA enzymes tethered to discretely positioned “signalosomes”.
This situation occurs only when the cAMP concentration in the vicinity of the relevant “signalosomes”
is high enough to swamp the PDE component, promoting downstream physiological effects [14].
The integration of PDE4 isoforms into specific “signalosomes” within the heart and the function of
these protein complexes will be the subject of this review.
3. PDEs and PDE4-Ology
PDEs are a large super-family of enzymes, which are the products of 11 different gene families,
grouped according to their structure, function, and affinity for cAMP and cGMP. Structurally, all PDEs
have conserved carboxy-terminal catalytic cores while their amino-terminal regions differ among
families, subfamilies, and specific isoforms. The N-terminal regions have a number of functional
roles. These include the targeting to specific subcellular locations and to signalosomes, and the
modulation of responses to signals from regulatory molecules or post-translational modifications [1,15].
cAMP-specific PDE4s make up the largest family with over 20 isoforms encoded by four genes (A, B,
C, and D). Each isoform has a unique N-terminal region, made up of an N-terminal targeting domain
(TD). Additionally, the N-terminal region contains upstream conserved regions 1 and 2 (UCR1 and
UCR2), which are linked to each other and to the catalytic domain by linker region 1 and 2 (LR1 and
LR2) respectively [16]. Based on the presence and size of UCR1 and UCR2, PDE4 isoforms can be
categorised into long, short, super-short, and dead-short isoforms (Figure 1); long isoforms have both
UCR1 and 2, short isoforms have only UCR2, super-short have a truncated UCR2, and dead-short
isoforms lack both UCR domains and have a truncated catalytic domain [17].J. Cardiovasc. Dev. Dis. 2018, 5, x FOR PEER REVIEW  3 of 14 
 
 
Figure 1. Diversity of domain organisation of PDE4 isoforms TD, transduction domain; LR1/2, linker 
region 1/2; UCR1/2, upstream conserved region 1/2. 
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interactions allow single isoforms to have multiple non-redundant roles in different tissues, cells and 
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function of small pools of highly active PDE4s has been considered as a novel way to circumvent 
side-effects observed following the systemic inhibition of global PDE4 activity using site-directed 
PDE4 inhibitors [28]. 
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information on individual isoforms and can often engender “bulk” cAMP effects due to 
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essential for holding signalling complexes together [32–34]. Another advantage of this technique is 
that it allows the informed design of cell-permeable disruptor peptides, which can interrupt these 
signalosome interactions. Disruptor peptides provide by far the most specific form of inhibition as 
only a specific localised pool of the PDE4 isoform of choice is displaced, leaving any other cellular 
effects of that isoform untouched [28,35]. 
The development of fluorescent probes which can monitor cAMP dynamics in real time have 
led to vast advancements in the field. Briefly, these probes contain two fluorescent moieties, a donor 
and an acceptor, and a cAMP binding domain. When cAMP binds, a conformational change is 
induced, altering the fluorescent energy transfer between the donor and acceptor, known as 
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UCR1 and 2 have a number of roles, including the regulation of functional outcomes following
PDE4 phosphorylation by protein kinase A (PKA) or extracellular signal-regulated kinase (ERK).
The presence or absence of these domains means that phosphorylation can have different, and even
opposite, functional effects in different isoforms [18–20].
The catalytic domain of PDE4 has been extensively studied, and X-ray crystal structures have
demonstrated the deep hydrophobic pocket made of numerous helices which makes up the active site
for the hydrolysis of cAMP [15,21]. The structure of this domain has been integral for the design of
family-specific inhibitors, which have been widely used both clinically and experimentally [22,23].
As previously mentioned, the subcellular localisation of PDEs is integral to their function in
shaping cAMP gradients and responses. This localisation is often directed by the N-terminal targeting
domains, which are highly varied among PDE4 isoforms [24,25], though targeting can also be driven
by other regions including the newly identified multi-functional docking domain positioned at
the C-terminal end of the catalytic unit [26]. Unique subsets of PDE4 specific interactions allow
single isoforms to have multiple non-redundant roles in different tissues, cells and even different
micro-domains within the same cell [27]. The disruption of this location dependent function of small
pools of highly active PDE4s has been considered as a novel way to circumvent side-effects observed
following the systemic inhibition of global PDE4 activity using site-directed PDE4 inhibitors [28].
4. Technological Approaches to Defining Roles for PDE4 Isoforms
Isoform specific roles of PDEs have been identified within the realm of the cardiovascular system
and historically, as new technologies have been invented, these have been used to identify specific
interactions and functions of PDE4. Often, the first and easiest approach utilised is pharmacological,
and employs family-specific inhibitors. However, this strategy gives little information on individual
isoforms and can often engender “bulk” cAMP effects due to simultaneous inhibition of all
PDE4 enzymes in all locations. Other more targeted approaches include siRNA knockdown and
overexpression of dominant-negative PDEs. Both of these allow diminution of the influence of
one isoform by either genetic silencing or displacement of endogenous, functional PDEs [29–31].
Often these approaches are sufficient to pinpoint specific cellular functions for single isoforms; however,
if one isoform has multiple roles in the same cell, an incomplete understanding of the complexity of
PDE4 action can be lost.
The identification of specific protein-protein interactions within PDE signalosomes has been
integral to understanding PDE4 function. Peptide array technology has proved to be an accurate way
to screen for such interactions and to predict the regions and specific amino acids which are essential
for holding signalling complexes together [32–34]. Another advantage of this technique is that it allows
the informed design of cell-permeable disruptor peptides, which can interrupt these signalosome
interactions. Disruptor peptides provide by far the most specific form of inhibition as only a specific
localised pool of the PDE4 isoform of choice is displaced, leaving any other cellular effects of that
isoform untouched [28,35].
The development of fluorescent probes which can monitor cAMP dynamics in real time have led
to vast advancements in the field. Briefly, these probes contain two fluorescent moieties, a donor and
an acceptor, and a cAMP binding domain. When cAMP binds, a conformational change is induced,
altering the fluorescent energy transfer between the donor and acceptor, known as fluorescence
resonance energy transfer (FRET). The detection of the two emissions allows real time changes in
cAMP concentration to be measured [36].
Many of the studies described in the present report employ a combination of these techniques to
create robust evidence for the specific roles of PDE4 isoforms in the cardiovascular system.
5. PDE4 in the Heart
Much of the understanding of cAMP compartmentalisation and the role of PDEs comes from
extensive studies of the signalling pathway in cardiac myocytes. Generally speaking, four PDE families
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have been identified as having notable roles in cAMP signalling in the heart: PDE1, PDE2, PDE3,
and PDE4 [37]. Despite the identification of localised expression of PDE4 in cardiac myocytes, inhibition
of this family was shown to have very limited effects on cardiovascular parameters, such as basal
blood pressure, heart rate, and contractility. This can be explained by the fact that PDE4 is a major
player not at basal cAMP levels, but during β-adrenergic stimulation, when intracellular [cAMP] is
raised. Additionally, it has been shown that redundancy of the PDE network can lead to compensatory
effects, in which other families with the same hydrolytic activity attenuate the effects of PDE4 loss of
function [38].
In the cardiac myocyte, sympathetic activation leads to β-adrenergic signalling, a major part of
the fight or flight response. Briefly, when the receptor is activated, its associated Gs-protein causes the
activation of AC, which catalyses the production of cAMP from ATP. cAMP in turn activates various
effector proteins; of major importance for this signalling paradigm is PKA, which phosphorylates a
number of substrates important for cardiac excitation-contraction coupling, and EPAC, which is of
particular importance in the vasculature. These phosphorylation effects lead to positive inotropic and
lusitropic effects, increasing the function of the heart for increased circulatory demands [39].
Interestingly, the phosphorylation of these substrate proteins by PKA is tightly regulated by PDE4
enzymes, which associate directly within signalosomes, modifying the signalling in tight compartments.
In this way, it is not global signalling which is affected by PDE4, but local, compartmentalised
signalling. This concept, developed in the 1980s by Hayes et al. using biochemical means was
proven unequivocally using advanced imaging techniques [12]. Optical probes that acted as cAMP
FRET reporters, allowed visualisation of the formation of cAMP gradients following submaximal
β-adrenergic stimulation. When used in combination with PDE inhibitors, it became apparent that the
loss of cAMP hydrolysis within cellular microdomains abrogated the spatial and temporal control of
cAMP dynamics that is required to channel receptor-specific physiological outcomes [13,40].
PDE4 and cardiac disease have a complicated relationship [41]. On one hand, PDE inhibition has
been shown to enhance cAMP signalling, resulting in increased cardiomyocyte function. In contrast,
chronic inhibition of PDEs results in increased mortality, often due to cardiac side effects [41,42].
Finally, PDE4 activity is decreased in heart failure, potentially contributing to disease progression due
to faulty regulation of the sympathetic induction of phosphorylation of cardiac excitation-contraction
coupling proteins [43,44].
The role of PDE4 in the cardiac myocyte cannot be described in full without delving into the
discrete roles of specific isoforms within their discrete subcellular compartments. The next sections of
this review will focus on these unique functions. A schematic summary of cardiac PDE signalosomes
is shown in Figure 2.
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receptor desensitisation. PDE4B regulates both the LTCC and RyR, which controls the process of 
calcium induced calcium release. PDE4D interacts with SERCA, regulating the reuptake of calcium 
into the SR. PDE4D3 interacts with IKs, modulating basal channel function. Finally, PKE4D5 
regulates the cardioprotective effects of HSP20. AC, adenylyl cyclase; AKAP, A-kinase anchoring 
protein; ATP, adenosine triphosphate; β-AR, β-adrenoceptor; β-Arr, β-arrestin; ERK, extracellular 
signal regulated kinases; Gi; inhibitory G-protein; Gs, stimulatory G-protein; HSP20, heat shock 
protein 20; IKS, cardiac IKS potassium channel; LTCC, L-type calcium channel; P, phosphorylation; 
PKA, protein kinase A PLN, phosphopamban, RyR, ryanodine receptor SERCA, sarcoplasmic 
reticulum calcium ATPase [35,43,45–49]. 
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loop is created when the receptor itself is phosphorylated by PKA. This phosphorylation switches 
the receptor’s signalling to an inhibitory G protein, Gi, which inhibits AC as well as activating other 
pathways, such as ERK1/2 [50]. Additionally, the phosphorylation of the receptor by G-protein 
coupled receptor kinases (GRKs) causes the recruitment of β-arrestin, which further desensitises the 
receptor by sterically hindering access to the G-protein [51]. However, when it was observed that the 
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translocation was a crucial function of β-arrestin [52]. In 2003, Baillie and colleagues used 
pharmacological inhibition and overexpression of dominant negative mutants to show that PDE4D5 
Figure 2. Cardiac PDE signalosomes. PDE4 family members have been shown to integrate
into macromolecular complexes with numerous cardiac proteins, many of which are involved in
excitation-contraction coupling and calcium handling. PDE4D5 interacts with β-arrestin, regulating
receptor desensitisation. PDE4B regulates both the LTCC and RyR, which controls the process of
calcium induced calcium release. PDE4D interacts with SERCA, regulating the reuptake of calcium
into the SR. PDE4D3 interacts with IKs, modulating basal channel function. Finally, PKE4D5 regulates
the cardioprotective effects of HSP20. AC, adenylyl cyclase; AKAP, A-kinase anchoring protein; ATP,
adenosine triphosphate; β-AR, β-adrenoceptor; β-Arr, β-arrestin; ERK, extracellular signal regulated
kinases; Gi; inhibitory G-pr tein; Gs, stimulatory G-prot in; HSP20, heat shock protein 20; IKS,
cardiac IKS potassium channel; LTCC, L-type calcium channel; P, phosphorylation; PKA, protein
kinase A PLN, phosphopamban, RyR, ryanodine receptor SERCA, sarcoplasmic reticulum calcium
ATPase [35,43,45–49].
5.1. PDE4D5’s Role in β-Adrenoceptor Desensitisation
One of the best understood functions of PDE4 in the cardiovascular system is the role of PDE4D5
in the regulation of β2-adrenergic signalling in the cardiac myocyte. When the β2-adrenoceptor is
stimulated, its coupled Gs protein stimulates AC, which produces cAMP to activate localised PKA.
Desensitisation of adrenergic signalling occurs when a negative-feedback loop is created when the
receptor itself is phosphorylated by PKA. This phosphorylation switches the receptor’s signalling to an
inhibitory G protein, Gi, which inhibits AC as well as activating other pathways, such as ERK1/2 [50].
Additionally, the phosphorylation of the receptor by G-protein coupled receptor kinases (GRKs)
causes the recruitment of β-arrestin, which further desensitises the receptor by sterically hindering
access to the G-protein [51]. However, when it was observed that the recruitment of β-arrestin also
increased local cAMP degradation, it became clear that PDE translocation was a crucial function of
β-arrestin [52]. In 2003, Baillie and colleagues used pharmacological inhibition and overexpression of
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dominant negative mutants to show that PDE4D5 is recruited to the β2-adrenoceptor by β-arrestin.
In neonatal rat ventricular myocytes (NRVM), both rolipram (a PDE4 inhibitor) and dominant negative
PDE4D5 increased the PKA phosphorylation of the receptor, and the activation of ERK1/2, which is
consistent with phenotypic switching of the receptor [53]. In a similar study, siRNA was used to
knockdown pan-PDE4D, which caused similar effects, namely, increased PKA phosphorylation of the
receptor and ERK activation. The same effects were achieved by the specific knockdown of PDE4D5
and this was the first time a function had been ascribed to an individual PDE4 isoform [29].
Interestingly, PDE4D5 is not the only isoform which has been shown to interact with β-arrestin.
In fact, all PDE4 isoforms have this ability due to the presence of the binding site in the conserved
catalytic region [52]. The presence of an additional β-arrestin binding site on PDE4D5’s unique
N-terminal binding domain could confer the specificity of its functioning as it is the “chosen-one” for
β-arrestin translocation [46]. Additionally, other pools of PDE4 which are expressed in the cell could
be preferentially sequestered in a different cellular location with different binding partners.
The direct interaction of the PDE with β-arrestin, however, is not sufficient to explain these
observations. The localisation of a pool of PKA to the β2-adrenergic receptor has been shown to
depend on the scaffolding protein, AKAP79 [29]. This allows the tethered PDE to regulate the activity
of this discrete pool of PKA. This determines the phosphorylation status and, thereby, the phenotypic
switching of the receptor.
5.2. PDE4D5 Regulates Cardioprotection by HSP20
Another example in which PDE4 has been shown to regulate the phosphorylation of a crucial
cardiac signalling protein is in the case of the small heat shock protein 20 (HSP20, HSPB6). HSP20 is
part of a diverse, ubiquitously expressed family of small chaperone proteins, whose expression patterns
are regulated by cellular stressors [54]. HSP20 has been shown to have a protective role in cardiac
myocytes, but only in its phosphorylated state [55–57]. In fact, when HSP20 is phosphorylated by PKA
at Ser16, it protects the cell by switching off harmful signalling (NF-kB) and switching on protective
signalling (Akt/PKB), inhibiting necrosis and apoptosis, and stabilising the cell’s cytoskeleton [58–61].
These protective mechanisms have been studied in the context of a variety of cardiac indications,
including ischaemia/reperfusion, chronic β-adrenergic stimulation, and heart failure [61–63].
The importance of phosphorylation has been shown in a variety of mutant studies, in which
a non-phosphorylated mutant (S16A) lost its protective effects in I/R injury, and constitutively
phosphorylated mutant (S16D) effectively protected cells from apoptosis [55,56].
The importance of PKA phosphorylation for HSP20’s cardioprotective abilities led researchers
to investigate the role of PDEs in this signalling pathway [35]. Initial experiments showed that
pharmacological inhibition of PDE4 augmented the isoprenaline-induced increase in phosphorylated
HSP20, confirming the functional role of PDE4. Real time monitoring of cAMP levels using FRET
technology gave more insight into PDE4’s role in this pathway. Comparing the response of a cAMP
FRET probe tethered to HSP20 with an untethered, cytosolic probe showed that PDE4 inhibition caused
a greater increase in cAMP in the vicinity of HSP20. This result highlights once again that the location
of small active pools of PDE4 is key to the enzyme’s control of specific events in cardiac myocytes.
The next step was to determine whether there was a direct interaction. Co-immunoprecipitation
studies were used in conjunction with peptide array experiments to show that HSP20 directly interacts
with the conserved catalytic region of PDE4D isoforms. The identification of the amino acids important
for the docking of HSP20 to PDE4D allowed the design and manufacturing of a cell permeable
peptide (peptide 906) which dismantles the interaction. Treatment of NRVM with this peptide not only
resulted in an increased phosphorylation of HSP20, but also an attenuation of hypertrophic response
to sustained β-adrenergic stimulation [64]. The peptide was also subsequently used in a rodent model
of heart disease with great effect [65].
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5.3. PDE4D3’s Regulation of RyR Phosphorylation
In the clinic, the use of PDE inhibitors has been plagued with cardiac problems, including
increased susceptibility to arrhythmia and heart failure. The underlying mechanisms were unknown
until Lehnart and colleagues performed an elegant study using PDE4D deficient mice [43]. It was
observed that these animals developed a dilated cardiomyopathy which had many characteristics
consistent with human chronic heart failure as well as exercise induced ventricular arrhythmias (VT).
Upon observation at the cellular level, it was shown that despite normal global cAMP signalling in
the PDE4D−/− mice, there was a marked increase in localised cAMP at the cardiomyocyte Z line.
This observation coupled with the evidence of previous studies showing that the ryanodine receptor
(RyR) is hyperphosphorylated by PKA at Ser2808 in heart failure led the researchers to study the role
of PDE4’s regulation of RyR phosphorylation in their model [66–69]. Indeed, the PDE4D−/− mice
showed both hyperphosphorylation of the RyR as well as diminished levels of calstabin-2 (FKBP12.6),
which functions to stabilise RyR and reduce calcium leak from the sarcoplasmic reticulum [70,71].
These changes led to multiple phenotypic observations. In terms of RyR function, the channels had a
“leaky” phenotype, similar to that which has been shown in heart failure and exercise induced sudden
cardiac death [66,70].
The individual isoform of PDE which associates with RyR to regulate these effects was identified
as PDE4D3. This is consistent with PDE4D3 being one of the three PDE4D isoforms expressed in the
heart; however, studies completed in rat hearts should be extrapolated with caution due to potential
differences in expression patterns of human hearts [72]. The elimination of PDE4D3 in complex with
RyR was shown to be highly relevant physiologically as PDE4D3 levels in the complex are also reduced
in human heart failure samples. This provided an interesting explanation for the hyperphosphorylation
of RyR by PKA despite globally decreased cAMP signalling in failing human cardiac myocytes, as had
been previously observed [73].
As the final piece of the puzzle, the group sought to confirm the role of hyperphosphorylated
RyR as a causative factor for the observed phenotypes. The PDE4D−/− mice were crossed with mice
harbouring a mutation which did not allow PKA phosphorylation of the RyR (S2808A). These mice
were protected against both exercise induced sudden cardiac death and myocardial infarction (MI)
induced sudden cardiac death, confirming the role of the PDE4D3, PKA, RyR signalosome in the
observed phenotypes.
The similarities of the phenotypes observed in PDE4D−/− mice with human cardiac disease
provide a compelling argument for the role of aberrant signalling relating to maladjustment of the
PDE complement within cardiac “signalosomes” in cardiomyopathy. Additionally, the identification of
PDE4D3 in complex with the RyR pinpointed another unique function for an individual PDE4 isoform.
5.4. PDE4D3 Regulates Basal IKs Activity
The electrical activity of cardiac myocytes is another function where PDE4 has an active
input. The slowly activating potassium channel (IKs) is a major repolarising current in the cardiac
action potential. IKs exists as a macromolecular complex which comprises KCNQ1 α-subunits
and KCNE1 β-subunits which interact with a variety of proteins that regulate the channel’s
function [74,75]. These include AC9, AKAP-9, PKA, and protein phosphatase-1 [76,77]. As with many
other cAMP signalling models in the cardiac myocyte, it was clear that a PDE may be involved
in this signalosome, thereby regulating PKA phosphorylation of the α-subunits. In a primarily
biochemical study, immunoprecipitation techniques identified that PDE4D3 is spatially confined
within this macromolecular complex via a direct interaction with AKAP-9 [49]. Functional experiments
in ventricular myocytes using pharmacological inhibitors showed that the PDE4 was able to fine tune
the functioning of the channel at basal conditions, probably due to a basally active AC in the vicinity.
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5.5. PDE4B Has a Dominant Role in LTCC Regulation
The L-type calcium channel (LTCC) is yet another cardiac excitation-contraction coupling protein
whose function is modified by a PDE4 isoform. This protein functions to allow calcium influx through
the cardiac myocyte membrane, which triggers the release of calcium from intracellular stores by
the RyR, in a process known as calcium-induced calcium release (CICR) [39]. Under conditions of
β-adrenergic stimulation, PKA phosphorylates the pore forming subunits of the LTCC, which increases
channel activity [78,79]. In combination with RyR phosphorylation, CICR is increased, leading to a
positive inotropic effect [39].
Although both PDE4B and PDE4D were both shown to tether to the LTCC signalosome, a study
using subfamily specific knockout mice showed that PDE4B exhibits the dominant functional role in the
regulation of LTCC phosphorylation and the protection against arrhythmia [47]. Firstly, experiments
in wild type mice showed that PDE4 inhibition had no effect on basal calcium current through the
LTCC (ICa,L) but markedly increased ICa,L under conditions of β-adrenergic stimulation. Consistently,
in both PDE4B−/− and PDE4D−/− mice, ICa,L was increased, leading to increased calcium transients
and increased contractility. The disease relevance of this research was shown using in vivo pacing
in the knockout animals, which resulted in ventricular tachycardia (VT) in PDE4B−/− mice but not
in PDE4D−/− mice. This study displayed the dominant functional role of PDE4B in the regulation
of phosphorylation of LTCC, which consequently regulates the entry of calcium into the cell and the
initiation of CICR.
The role of PDE4B in the protection against arrhythmia is consistent with the observation of
decreased PDE4B activity in cardiac hypertrophy [44]. The combination of these two findings could
represent at least a partial explanation of the incidence of arrhythmia and sudden cardiac death
associated with heart failure.
5.6. PDE4D and PDE3A Regulate PLN Phosphorylation and SERCA Function
The regulation of sarcoplasmic reticular calcium ATPase (SERCA) function relies on both PDE3
and PDE4 isoforms, unlike in other cardiac PDE signalosomes.
SERCA is a calcium channel on the sarcoplasmic reticular membrane which functions to sequester
calcium in its intracellular store. Phospholamban (PLN) inhibits its activity, tightly regulating channel
function. PLN can be phosphorylated by PKA, which reduces its inhibitory influence, leading to
increased SERCA activity and enhanced sarcoplasmic reticulum (SR) calcium load and contractility [80].
Both PDE4D and PDE3A have been shown to integrate into a signalosome containing SERCA,
PLN, PKA and other structural and regulatory proteins, thereby regulating PLN phosphorylation and
exhibiting a regulation of basal contractile function [48,81]. In separate studies, members of both PDE
subfamilies were detected in SERCA immunoprecipitates, showing that these PDEs integrate into the
SERCA/PLN signalosome. Knockout of PDE3A in rodents resulted in increased phosphorylation
of PLN associated with increased SERCA activity, SR calcium load, and increased contractility,
suggesting a major role for this isoform in the SERCA microdomain. However, similar studies in
PDE4D knockout rodents produced strikingly similar results, from increased PLN phosphorylation
to increased contractility. Taken together, it is apparent that both PDE3A and PDE4D are important
modulators of cAMP signalling at the SERCA microdomain as both seem to have comparable effects.
Further studies will be necessary to dissect any unique, non-compensated roles of these PDE isoforms
on SERCA function.
As evidenced by the examples above, highly localised pools of PDEs and in particular PDE4
have influence on many steps of the cardiac excitation-contraction coupling process. Although the
identity of the PDE4 isoforms differ in the distinct locations, the underlying concept of dormant
signalosomes being activated following the inhibition, displacement, silencing or overwhelming of a
spatially restricted PDE4 cohort prevails. Clearly, the initial concept pioneered by Hayes et al. and
subsequently validated using optical cAMP probes has also been upheld in diseases that occur as a
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result of the malformation of highly tuned cAMP gradients underpinned by loss of localised PDE4
machinery [12].
6. Vascular cAMP Signalling and PDEs
Although cardiac myocytes have taken centre stage in terms of PDE4 research, this group of
enzymes also has major roles in the wider cardiovascular system, regulating many characteristics of the
vasculature. cAMP signalling is particularly important in the signalling systems of vascular endothelial
cells (VECs) where increases in cAMP concentration results in reduced vascular permeability.
The literature is clear that PDEs are integral to the fine control of such processes [82]. In conditions
of low cGMP, PDE4 is the major regulator of PKA and EPAC activation, both of which influence
permeability. In addition to PDE4, PDE2 and PDE3 activity also impinge on VEC permeability,
but their influence is changed by increases in cGMP, which activates PDE2 and inhibits PDE3, allowing
fine tuning of regulation [82,83]. As in cardiac myocytes, localised signalosomes have been identified
as crucial in the maintenance of signalling specificity. The components of compartmentalised signalling
complexes in this location include various AC subtypes, PDE2, PDE3, and PDE4 isoforms, and AKAPs.
An important study by Maurice and colleagues identified the unique, non-compensated role of PDE4D
in the regulation of vascular permeability, confirming the notion of compartmentalised signalling in
VECs [3,83].
PDE4D’s Role in the Regulation of Vascular Permeability
VEC permeability is largely mediated through adherens junctions (AJ), structures comprised
of vascular endothelial cell cadherins (VECAD) which interact with those of neighbouring cells and
assemble a complex containing catenins and actinins to the cytoskeleton [84,85]. When VECs are
stimulated by agents that increase cAMP, the activation of PKA and EPAC results in the stabilisation of
AJs, decreasing cell permeability [83]. Pharmacological inhibition and siRNA-mediated knockdown
identified PDE4D and EPAC1 as the mediators of cAMP-dependent changes in permeability [3].
Interestingly, the use of pharmacological inhibition of PDE4 and knockdown of PDE4D yielded
conflicting results. As expected, PDE4 inhibition decreased cell permeability; however, in stark contrast,
knockdown of PDE4D increased cell permeability. This was explained by a dual role of PDE4D in this
cellular compartment. Not only does the PDE regulate EPAC1 activation by hydrolysing cAMP, but
it also acts as the tether, localising EPAC1 to the VECAD structures. The identification of PDE4D’s
function as a scaffold identified a novel role for the family of enzymes. Maurice et al. also employed a
disruptor peptide to determine the function of the interaction between EPAC1 and PDE4D. Treatment
with this peptide reduced VEC permeability to a similar degree as global PDE4 inhibition (Figure 3).
The specific disruption of the PDE4D-EPAC1 interaction proved to be a novel method to alter VEC
permeability and barrier function.
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7. Future Directions and Outlook
As described in the present review, the study of PDE4 in the cardiovascular system is centered
on the discovery of isoform specific roles within signalosomes. Compartmentalisation of distinct
PDE4 isoforms underpin their function and allow low cellular concentrations of the enzyme to have a
pivotal role in many areas of cardiac signaling. Future development of new technologies, such as the
expansion of novel, highly targeted FRET probes, will allow the effects of PDEs on cAMP signalling
to be observed in novel ways that were not previously possible [86]. In conjunction with PDE4 gene
therapy, PDE4 activators and novel animal models where inducible dominant negative PD4 constructs
are expressed, our understanding of the currently accepted roles of PDEs will be increased, and novel
roles at additional microdomains will inevitably be uncovered. This information will undoubtedly
drive novel therapeutic endeavors to target this versatile enzyme family for the good of humankind.
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